Rainer Vogel, MD
Pain Medicine · Henderson, NVNPI 1396727756
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $161,087 of the $230,139 with a category attached, or 70.0%. 55 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 37.5% of the total. Reporting peaked in 2019 at $136,554 and has fallen 89.9% since, to $13,808 in 2025. Among pain medicine clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 742 payments — averaging $310.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$86K
- Medtronic$75K
- Pacira Therapeutics, Inc.$19K
- Nevro Corp.$18K
- Aurora Spine, Inc.$17K
- Kaleo, Inc.$4K
- plus $12K from 49 others
Across 68 payments — averaging $1775.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$81K
- Boston Scientific$26K
- Nevro Corp.$9K
- Curonix LLC$2K
- Painteq LLC$2K
- Stimwave Technologies Incorporated$1K
What the payments were for
- Consulting fees$19,2158%
- Speaking & faculty fees$161,08770%
- Travel & lodging$26,39011%
- Food & beverage$23,43510%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUCEMYRA$57,773
- RELISTOR$38,145
- ADAPTIVESTIM$27,412
- INTELLIS ADAPTIVESTIM$21,909
- Zilretta$18,359
- ZIP$16,862
- Senza Spinal Cord Stimulation System$16,232
- KYPHON EXPRESS II KYPHOPAK TRAY$9,353
- INTELLIS$6,999
- Intracept$5,615
- EVZIO$3,860
- SYNCHROMEDII$2,500
- SYNCHROMED$1,437
- Durolane$1,044
- Omnia$566
- Qutenza$462
- StimQ Receiver Stimulator Kit Channel A US w Receiver$393
- StimQ Freedom 8A Receiver Kit Channel A US w Receiver$393
- Freedom 4A Receiver Kit Channel A US w Receiver$393
- Freedom 8A Receiver Kit Channel A US w Receiver$393
How this compares
$230,139 in reported general payments places this provider in the 95th percentile of 101 pain medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 756 | $30,463 |
| MovantikNaloxegol Oxalate | 49 | $19,952 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 546 | $17,585 |
| BotoxOnabotulinumtoxina | 11 | $14,293 |
| Oxycodone Hcl | 479 | $10,610 |
| Duloxetine Hcl | 715 | $10,453 |
| Gabapentin | 762 | $10,016 |
| Diclofenac Sodium | 533 | $9,187 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,309 |
| Fentanyl | 58 | $4,437 |
| Tizanidine Hcl | 490 | $3,731 |
| Morphine Sulfate | 102 | $3,635 |
| Morphine Sulfate ErMorphine Sulfate | 175 | $3,564 |
| Pregabalin | 143 | $3,434 |
| Buprenorphine | 24 | $3,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $169 | $19,95249 claims |
| AbbVieBotox | $134 | $14,29311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 pain medicine providers in Nevada.
Other pain medicine in Henderson
- Daniel FabitoHenderson$15K
- Virginia HardieHenderson$9K
- Scott MartinHenderson$6K
- Tomas KuceraHenderson$5K
- Denis PattersonReno$816K
- John DimuroPahrump$44K
- Anwar MackReno$32K
- Kunal ParikhLas Vegas$26K
- Hashim QureshiN Las Vegas$25K
- Nader HelmiLas Vegas$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.